Researchers have found in a new study that Intraperitoneal (IP) therapy demonstrated better efficacy than MSII in improving both renal function and glycemic control in patients with early-stage ...

Osteoarthritis affects around 600 million people globally. It causes pain, stiffness and reduced joint function – most commonly in the knees, hands and hips. There’s currently no cure for ...

Knee osteoarthritis is a complex disease that affects the whole joint, including bone, cartilage, ligaments and muscles. Osteoarthritis is a common cause of pain and movement difficulty, affecting 8.3 ...

While GLP-1 weight loss meds have been a mainstay in pop culture for a few years now, they're potentially about to get even more widespread. Formerly only available as an injection, Wegovy recently ...

A second-generation intraperitoneal insulin pump — the next-generation MiniMed Implantable Insulin Pump System (MIIPS 2020), which is not yet commercially licensed but can be obtained in some cases on ...

Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up. Randomized phase 2 study of gemcitabine with or ...

The primary difference between the Wegovy pill and the injection is how you take them and how often. The Wegovy pill is a daily tablet you swallow, while the Wegovy injection is a once-weekly shot you ...

GLP-1 (glucagon-like peptide-1 receptor agonists) like Ozempic and Wegovy continue to make headlines as more research points to the benefits of taking these medications. Traditionally, patients ...

Kristie Reed, PharmD, oversees emergency, general medical, surgical, psychiatric care, and oncology medication as the pharmacy director of a community hospital. Dr. Reed specializes in IV medications.

A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C–mutated metastatic colorectal cancer (CodeBreaK 301). This ...